GPS_OS_21_vs_SOC_5
Posted - 10 hours ago
$SLS Dr. Zeidner who Lead the Revumenib Phase 2 Trials for $SNDX and Got Fda Approval last week for 21% CR rates in the KMT2a AML Subset, is Also the Lead investigator for SLS009, CDK9 Inhibitor, and he is Presenting P2 data - 100% Complete Response Rates for the Optimally Dosed ASXL1+ AML Subset - will be Major news, many of the 30,000 #ash2024 attendees will have not yet heard this Clinic Changing news, - they will this week. https://ash.confex.com/ash/2024/webprogram/Paper198686.html ~13,400 ASXL1+ AML Diagnoses each year ~ 17,400 ASXL1+ MDS Diagnoses each year
GPS_OS_21_vs_SOC_5
Posted - 17 hours ago
$SLS $NVCR up $1.7B in market value, today, in 1 day, on P3 data, $SNTI up 600% today, on a Phase 1, 3 patient result for R/R AML.. . meanwhile, Highbridge Jpm just disclosed a 9.99% equity stake, SLS Insiders are purchasing shares, short volume is very low only about 10%, SLS009 Phase 2, 100% CR rates for dying ASXL1+ R/R AML Patients are Already worth 15x to 20x the current share price, Right Now - look at $SNDX fda approval on P2, 21% CR data... and Gps FDA Registrational Phase 3 Trial results worth Literal Billions are due any day, by Q4. its Dec 2. $BTC.X 1 single Bitcoin invested in SLS right now could be worth $10M + at some point this month.
jewell69
Posted - 1 day ago
$SNDX buy low / sell / high / buy back AgAIN low ! 12/02/2024 Buy Trade Details SNDX SYNDAX PHARMACEUTICALS I 275 $16.32 -$4,488.00 10/24/2024 Sell Trade Details SNDX SYNDAX PHARMACEUTICALS I 275 $19.2192 $0.20 $5,285.08 10/23/2024 Buy Trade Details SNDX SYNDAX PHARMACEUTICALS I 275 $18.67 -$5,134.25
BraveEchoer
Posted - 1 day ago
$SVRA $SNDX 🔥MYNZ I'm buying! 🚀 A 40:1 RS is set for Dec 3, with big news likely to follow. Think about it something big seems to be in motion. Let’s break it down: a $30M offering, then a Thermo Fisher (TMO) partnership, Thermo backed by BlackRock and Vanguard. Think they’ll step aside? Post-RS, 80M shares shrink to a 2M tiny float. Expect news on the offering and more, possibly reshaping Mainz's path. This could hit $50/share. FOMO is real I'm adding now!
GPS_OS_21_vs_SOC_5
Posted - 1 day ago
$SLS $SNTI now up 550% on 3 Patient P1 data... for R/R AML Flt3. Meanwhile SLS009 Phase 2, 30 Patient data, has a 100% Complete Response rate for ASXL1+ R/R AML patients who FAILED all Previous Treatments, Less Healthy than the SNTi Set. SLS is worth 15 - 20x the current Market Cap $SNDX and $Kura are direct Phase 2 AML SUBSET, Market Comps with Billion Dollar Market Caps.
JuggernautRaider
Posted - 1 day ago
@ekpemofolo , ask @NoorAlTrades or @DoctorDueDiligence : I am the real deal.
Here’s my blueprint I released with “Uncle Rolli Greer”. I worked at $KPTI until July 2023 - Uncle Rolli was there much longer.
It is an easy company to fix. It is poorly run. Barry Greene on the board is also the CEO for $SAGE ; Richard is on another board too. This is a red flag: being a biotech CEO should be a 100 an hour per week job.
Or…. $SNDX , $INCY, or $BMY (another company I worked at :) should just buy them for $1.25
Here’s my linkedin post.
https://www.linkedin.com/posts/jeffrey-jay-conroy-80a39323_ive-gotten-some-incredible-feedback-from-activity-7256358740956737536-NuOF?utm_source=share&utm_medium=member_ios
Groot76
Posted - 11/29/24
$SNDX it's time to head towards 20$, and then retest 25$
TomMac64
Posted - 11/29/24
$SLS $SNDX
Cabasada
Posted - 11/29/24
$SNDX the same old Pumper from $SLS is pumping hard!
GPS_OS_21_vs_SOC_5
Posted - 11/27/24
$SLS SLS009 Phase 2, 100% Complete Response rates for dying, end Stage ASXL1+ R/R AML Patients, who have failed all other treatments, Being Published at ASH - is worth 15 - 20x the current short rigged $85M mcap. - Revumenib $SNDX just got FDA Approval at 21% CR and 4.7months duration of response among CR Patients. - it was worth 1.5B when it Published P1 data -- and Today, SLS CEO on Linkdin. Congratulations to our team for additional exciting data around ASXL1 and our SLS009 program. ASXL1 mutation may be playing a key preselection/biomarker role with our highly selective CDK9 inhibitor, SLS009 – both in hematological and solid cancers. We observed high efficacy of SLS009 in 67% of ASXL1 Mutated Solid Cancers, including colorectal cancer (57%) and non-small cell lung cancer (100%). Our ASXL1 mutation-treatment approach is now further validated for potential biomarker use for SLS009’s drug response in solid cancers as well as hematological malignancies.
GPS_OS_21_vs_SOC_5
Posted - 11/27/24
$SLS If you weren't aware, SLS009 has Phase 2 100% Complete Response Rates for ASXL1+ AML patients, about 13K per year diagnosed. $SNDX just got FDA Approval for 21% Cr Rates in an another AML subset, for its Phase 2 Data. Right NOW - SLS009 is worth 15x the current short Rigged MCap The market has not realized this value, yet. Add in 40,000 Solid Cancer Patients MSI-H CRC, NSCLC.
GPS_OS_21_vs_SOC_5
Posted - 11/27/24
$SLS $SNDX $KURA ?
GPS_OS_21_vs_SOC_5
Posted - 11/26/24
$SLS Dr. Zeidner, running the SLS009 Phase 2B trial, is the same Dr' Who led the $SNDX Revumenib P2B trial, that just Got FDA Approval for KMT2a AML - with a 21% CR Rate. -- The Entire ASH Conference is going to be Ecstatic when they discover the -- SLS009 100% CR Rates for the END Stage, Dying ASXL1+ R/R AML Patients -- 100% CR Rates are worth north of a Billion Right Now
Groot76
Posted - 11/26/24
$SNDX come oooon! Is someone buying this stock????
GPS_OS_21_vs_SOC_5
Posted - 11/26/24
$SLS When do you think the whole market Will Realize SLS009 100% Complete Response Rates for Dying, End stage, R/R AML Patients is worth closer to a billion than $80M? - Dr Z and K both Said, 009 only needed 25% response rates or better for Fda Approval, P2A results are in at 100%. $kura Was a 1.5B company when it released its Phase 1 Data Same with $SNDX, it had a 1B Market cap when it published P1 data - that wasn't nearly as Good as SLS009. - - and the Overall Survival, for the low dose cohorts, who had a 10% Response Rates are already 2X Better - I think ASH will be 009's Coming out Party...
GPS_OS_21_vs_SOC_5
Posted - 11/25/24
$SLS While we're Waiting for Gps Immunotherapy AML Remission Phase Registrational Results Due ANY Day. -- anyone interested in real investing, actually investing in Undervalued Equity, take a look at these two comps. $SNDX $KURA -go back and look at the Co Value when they released their p1 and P2a data --- Both Companies were worth north of 1.5B while in Phase 2, for small AML Subsets. SLS just published P2 DATA at ASH confirming 100% Complete Remission Rates for ASXL1+ AML, 13,400 Patients are diagnosed each year with this Mutation, + another 17,400 MDS. -- SLS009 100% CR Rates for End Stage, Dying R/R ASXL1+ AML Patients who have a 2.5 month Life Expectancy - Right NOW - are worth 15X the current Short Manipulated Share price... $SNDX $KRON $VINC
Groot76
Posted - 11/25/24
$SNDX Let's squeeze them all!!
Groot76
Posted - 11/25/24
$SNDX yessss, this looks like a delayed mini short squeeze
Jarvis7424
Posted - 11/25/24
$SNDX this is a $25+ stock
Groot76
Posted - 11/23/24
$SNDX
Groot76
Posted - 11/23/24
$SNDX ...revumenib 2026 sales could exceed 500M annually, and maret price is just 1,4B....
Groot76
Posted - 11/22/24
$SNDX... It's time for the big squeeze!
uyaredude
Posted - 11/22/24
$SNDX i am speechless. the equities i sold to buy this POS made minimum 8% while this crapola, went down. It means the PTs of the analysts are completely irrelevant and not respected by the investors....I am selling today so the others can money.
Jarvis7424
Posted - 11/21/24
$SNDX how this stock isn’t $25+ yet blows my mind
flytrader1
Posted - 11/21/24
$SNDX A KURA takeover seems to be off the table with their licensing deal yesterday. Syndax's attractiveness has increased substantially! End of year biotech M&A usually is robust.
Groot76
Posted - 11/21/24
$SNDX ....rubbish, garbage, basura, monnezza....
quickaspeter
Posted - 11/21/24
$AUTL $IOVA $KURA $SNDX $SWTX Great post…thanks for sharing.
Polip
Posted - 11/21/24
$SNDX who is the crazy selling here? cmon